OS Therapies is a clinical stage oncology company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. OST-HER2, the Company’s lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. The Company has completed enrollment for a 41-patient Phase 2b clinical trial of OST-HER2 in resected, recurrent osteosarcoma, with results expected in the fourth quarter of 2024. OST-HER2 has completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing strong preclinical efficacy data in various models of breast cancer. OST-HER2 has been conditionally approved by the U.S. Department of Agriculture for the treatment of canines with osteosarcoma. In addition, OS Therapies is advancing its next generation Antibody Drug Conjugate (ADC) platform, known as tunable ADC (tADC), which features tunable, tailored antibody-linker-payload candidates. This platform leverages the Company’s proprietary silicone linker technology, enabling the delivery of multiple payloads per linker. For more information, please visit www.ostherapies.com.
Company profile
Ticker
OSTX
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Wealthbridge Acquisition Ltd
SEC CIK
Corporate docs
IRS number
825118368
OSTX stock data
Analyst ratings and price targets
Latest filings (excl ownership)
8-K
OS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of Directors
28 Oct 24
8-K
Other Events
22 Aug 24
8-K
OS Therapies Reports Second Quarter 2024 Financial Results
15 Aug 24
10-Q
2024 Q2
Quarterly report
14 Aug 24
424B4
Prospectus supplement with pricing info
1 Aug 24
EFFECT
Notice of effectiveness
1 Aug 24
CERT
Certification of approval for exchange listing
30 Jul 24
8-A12B
Registration of securities on exchange
30 Jul 24
S-1/A
IPO registration (amended)
13 Jun 24
S-1/A
IPO registration (amended)
7 Jun 24
Latest ownership filings
Financial summary
Quarter (USD) | Jun 24 | Mar 24 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | |||
---|---|---|---|---|---|---|
Cash on hand (at last report) | 94.93 k | 94.93 k | ||||
Cash burn (monthly) | 1.77 k | 259.93 k | ||||
Cash used (since last report) | 7.05 k | 1.04 mm | ||||
Cash remaining | 87.87 k | -941.40 k | ||||
Runway (months of cash) | 49.7 | -3.6 |
Institutional ownership, Q2 2024
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 Aug 24 | John Ciccio | Common Stock | Conversion | Acquire C | Yes | No | 0 | 30,264 | 0.00 | 435,835 |
2 Aug 24 | John Ciccio | Common Stock | Conversion | Acquire C | Yes | No | 0 | 266,306 | 0.00 | 405,571 |
2 Aug 24 | John Ciccio | Common stock, par value $0.001 per share ("Common Stock") | Conversion | Acquire C | Yes | No | 0 | 101,765 | 0.00 | 139,265 |
2 Aug 24 | Theodore F. Search | Common Stock | Conversion | Acquire C | Yes | No | 0 | 30,264 | 0.00 | 435,835 |
2 Aug 24 | Theodore F. Search | Common Stock | Conversion | Acquire C | Yes | No | 0 | 266,306 | 0.00 | 405,571 |
2 Aug 24 | Theodore F. Search | Common stock, par value $0.001 per share ("Common Stock") | Conversion | Acquire C | Yes | No | 0 | 101,765 | 0.00 | 139,265 |
News
12 Health Care Stocks Moving In Thursday's Intraday Session
3 Oct 24
EF Hutton Maintains Buy on OS Therapies, Maintains $21 Price Target
3 Oct 24
OS Therapies Announces Completion Of Phase 2b Clinical Trial For OST-HER2 In Recurred Osteosarcoma; Preparing To Request FDA Type C Meeting And Adjust Protocol; Data Analysis And Topline Results Expected In Q4 2024
3 Oct 24
EF Hutton Maintains Buy on OS Therapies, Maintains $21 Price Target
16 Sep 24
EF Hutton Initiates Coverage On OS Therapies with Buy Rating, Announces Price Target of $21
3 Sep 24
Press releases
OS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of Directors
28 Oct 24
OS Therapies to Present at the LD Micro Main Event XVII
24 Oct 24
OS Therapies to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
17 Oct 24
OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Completes Last Patient Visit
3 Oct 24
OS Therapies Announces Development of Two Novel Tunable Antibody Drug Conjugate (tADC)-Based Therapeutic Candidates
13 Sep 24